Experimental infections for the evaluation of beta-lactamase resistance.

AUTOR(ES)

Xerri, L

RESUMO

The antibacterial activity and pharmacokinetics of the beta-lactamase-stable cephalosporin cefuroxime and the gram-negative beta-lactamase-susceptible cephalosporin cefazolin were compared in two contrasting infection models in which Proteus morganii 82, which produces chromosomally mediated beta-lactamase, was the pathogen. In the rat paw model, characterized by high numbers of localized bacteria, cefazolin was destroyed at the site of infection and consequently did not produce a therapeutic response. In the mouse intraperitoneal model cefazolin was also inactive, despite peritoneal concentrations being unaffected by high counts of the beta-lactamase-producing P. morganii in the body cavity. In contrast the pharmacokinetics of cefuroxime was unaffected by the presence of the beta-lactamase-producing P. morganii, and good therapeutic responses were seen in both models.

Documentos Relacionados

• Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance.
• Plasmid-determined beta-lactamase indistinguishable from the chromosomal beta-lactamase of Escherichia coli.
• Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections.
• beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.
• Experimental Prediction of the Evolution of Ceftazidime Resistance in the CTX-M-2 Extended-Spectrum Beta-Lactamase